Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 21, 2025
Finance
Antiviral, oncology company Genuine plots Hong Kong listing: Public Equity Report
Plus: Xtalpi, Solid and Arcus all raise cash
BioCentury | Dec 31, 2024
Finance
Biotech raises make 2024 the year of the PIPE
BioCentury’s final Public Equity Report of the year tallies up fundraising activity
BioCentury | Dec 10, 2024
Deals
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | Nov 23, 2024
Finance
Latest Jeito bet positions European VC for fourth exit
Mega-round for Alentis spotlights French firm’s investment style
BioCentury | Jul 16, 2024
Deals
Deals report: Ipsen gets second ADC; Context buys MSLN
Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | Jun 11, 2024
Emerging Company Profile
Adcytherix: Emergence team reunites for another ADC company
French biotech to pursue novel targets with ADCs incorporating new and old payloads
BioCentury | Jun 5, 2024
Emerging Company Profile
Tubulis: Enhancing ADC stability via new conjugation methods
German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads
BioCentury | May 23, 2024
Product Development
Hummingbird’s dual ADC payloads deliver one-two punch to tumors
Singapore biotech aiming to overcome drug resistance by creating therapies carrying multiple payloads with orthogonal MoAs
Items per page:
1 - 10 of 189